![IL-6 antagonists may have a role in fighting COVID-19 after all](https://cdn.cancerletter.com/media/2020/09/24204026/36-COVID-sun_4x3.jpg)
![IL-6 antagonists may have a role in fighting COVID-19 after all](https://cdn.cancerletter.com/media/2020/09/24204026/36-COVID-sun_4x3.jpg)
Cover Story
COVID-19 & CancerFree
Earlier this year, as doctors observed that patients afflicted with the novel coronavirus were dying from a cytokine release syndrome, some suggested focusing on suppressing production of interleukin-6 to control this immune response gone haywire.
Free
By Alexandria Carolan
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop